Table 4.

Further details of applied treatment

Author/s	Bone defect		Mean latency period (range) (days)	Type of Ilizarov treatment (n,  %)
	Incidence (%)	Mean size (range) (cm)		Bifocal	Trifocal	Bifocal or trifocal (nr)
Madhusudhan et al.	100	4 (2–11)	nr (5–7)	22 (100)	0 (0)	0 (0)
Pirwani et al.	100	4.5 (2–8)	nr	16 (100)	0 (0)	0 (0)
Bumbasirevic et al.	100	6.9 (4–11)	7	30 (100)	0 (0)	0 (0)
Megas et al.	100	5 (2–12)	nr (3–5)	6 (66.6)	0 (0)	3 (33.3)
Lin et al.	100	8 (4–12)	7	8 (50)	8 (50)	0 (0)
Babar et al.	100	5.8 (nr)	7	17 (100)	0 (0)	0 (0)
Feng et al.	100	6.6 (3–12)	7	21 (100)	0 (0)	0 (0)
Krappinger et al.	100	6.6 (3–14.7)	nr (10–14)	15 (100)	0 (0)	0 (0)
Selim	100	9 (6–12)	7	0 (0)	10 (100)	0 (0)
Shadid et al.	nr	nr	nr	0 (0)	0 (0)	12 (100)
Spiegl et al.	100	5.3 (3–13)	7	25 (100)	0 (0)	0 (0)
Xu et al.	100	6.4 (3–12)	7	0 (0)	0 (0)	30 (100)
Yin et al.	100	6.27 (3–13)	nr (7–10)	66 (100)	0 (0)	0 (0)
Morsy	100	4.6 (4–7)	nr (7–10)	12 (100)	0 (0)	0 (0)
Marais et al.	100	7 (5–8)	7	7 (100)	0 (0)	0 (0)
Azzam et al.	100	7.4 (3.–12)	7	30 (100)	0 (0)	0 (0)
Bernstein et al.	100	5.9 (1.6–13)	nr	30 (100)	0 (0)	0 (0)
Khan et al.	100	3.2 (2–5)	nr	8 (33.3)	0 (0)	16 (66.6)
Peng et al.	100	9.2 (6–15)	10 (nr)	58 (100)	0 (0)	0 (0)
Wani et al.	100	5.1 (3–8)	7	18 (75)	0 (0)	8 (25)
Aboumira et al.	100	6.5 (3–17)	nr (12–14)	16 (64)	9 (36)	0 (0)
Aktuglu et al.	100	7.01 (5–18)	nr (5–7)	24 (100)	0 (0)	0 (0)
Fürmetz et al.	100	9 (3.1–13.4)	7	8 (100)	0 (0)	0 (0)
Rohilla et al.	100	7.27 (6–12)	7	35 (100)	0 (0)	0 (0)
Tetsworth et al.	100	7 (3–10)	nr	21 (100)	0 (0)	0 (0)
Yilihamu et al.	100	nr (> 3)	10	14 (100)	0 (0)	0 (0)
Zhang et al.	100	10.9 (6–20)	nr (7–10)	0 (0)	16 (100)	0 (0)

nr not reported